









Markets
/
Stocks
/
nasdaq-cnsp
/

CNS Pharmaceuticals Inc

CNSP

6.600USD

-0.570-7.95%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

277.42KMarket Cap

LossP/E TTM



CNS Pharmaceuticals Inc

6.600

-0.570-7.95%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of CNS Pharmaceuticals Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

CNS Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

289 / 501

Overall Ranking

525 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

52.000

Target Price

+625.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

CNS Pharmaceuticals Inc Highlights

StrengthsRisks

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Overvalued

The company’s latest PE is 0.02, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 42.73K shares, increasing 44.64% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

CNS Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 7.29, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is 0.02, which is 2.65% below the recent high of 0.02 and 142.04% above the recent low of -0.01.

Score

Industry at a Glance

Previous score

7.29

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 289/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for CNS Pharmaceuticals Inc is 52.00, with a high of 84.00 and a low of 20.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

52.000

Target Price

+625.24%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

CNS Pharmaceuticals Inc

CNSP

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 1.08, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 9.96 and the support level at 7.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.10

Change

-0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.580

Sell

RSI(14)

30.043

Neutral

STOCH(KDJ)(9,3,3)

6.387

Oversold

ATR(14)

0.514

High Vlolatility

CCI(14)

-166.547

Sell

Williams %R

96.700

Oversold

TRIX(12,20)

-0.571

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

7.316

Sell

MA10

7.788

Sell

MA20

8.668

Sell

MA50

8.162

Sell

MA100

6.084

Buy

MA200

4.232

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 7.44%, representing a quarter-over-quarter increase of 392.91%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Armistice Capital LLC

33.83K

+1811.47%

UBS Financial Services, Inc.

2.67K

+33.88%

Virtu Americas LLC

1.95K

Geode Capital Management, L.L.C.

1.49K

Two Sigma Investments, LP

1.30K

Cortice Biosciences, Inc.

956.00

HRT Financial LP

905.00

Tower Research Capital LLC

562.00

+31.92%

Barrett & Company, Inc.

8.00

Climaco (John Michael)

8.00

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.77. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.